JPH08509230A - 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法 - Google Patents
医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法Info
- Publication number
- JPH08509230A JPH08509230A JP6523593A JP52359394A JPH08509230A JP H08509230 A JPH08509230 A JP H08509230A JP 6523593 A JP6523593 A JP 6523593A JP 52359394 A JP52359394 A JP 52359394A JP H08509230 A JPH08509230 A JP H08509230A
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- composition
- compound
- drug
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.被包された生物学的活性水溶性化合物を含有するリポソーム組成物であって 、 このリポソーム組成物がさらに、内部に被包されたシクロデキストリンを含み ;かつ該生物学的活性化合物が、前記リポソーム組成物から、シクロデキストリ ン遊離リポソーム組成物からよりも、より遅い速度で放出されるような、リポソ ーム組成物。 2.前記リポソーム組成物が、単層膜、多重層及び多胞体リポソームの群から選 択された、請求の範囲第1項記載の組成物。 3.前記生物学的活性化合物の水への溶解度が、シクロデキストリン非存在下で 、1μg/ml以上である、請求の範囲第1項記載の組成物。 4.前記リポソームが、多胞体である、請求の範囲第1項記載の組成物。 5.前記化合物が、抗腫瘍薬、抗感染症薬、抗うつ薬、抗ウイルス薬、抗侵害受 容薬、抗不安薬及びホルモンからなる群から選択された、請求の範囲第1項記載 の組成物。 6.前記化合物が、抗腫瘍薬である、請求の範囲第1項記載の組成物。 7.前記化合物が、抗感染症薬である、請求の範囲第1項記載の組成物。 8.前記化合物が、抗ウイルス薬である、請求の範囲第1項記載の組成物。 9.前記化合物が、抗不安薬である、請求の範囲第1項記載の組成物。 10.前記化合物が、抗うつ薬である、請求の範囲第1項記載の組成物。 11.前記化合物が、ホルモンである、請求の範囲第1項記載の組成物。 12.前記化合物が、抗侵害受容薬である、請求の範囲第1項記載の組成物。 13.前記シクロデキストリンが、該組成物中に、約10mg/ml〜約400mg/mlの量で 存在する、請求の範囲第1項記載の組成物。 14.前記シクロデキストリンが、α-シクロデキストリン、β-シクロデキストリ ン、γ-シクロデキストリン、メチルシクロデキストリン、エチルシクロデキス トリン、ヒドロキシエチルシクロデキストリン、ヒドロキシプロピルシクロデキ ストリン、分枝したシクロデキストリン、シクロデキストリンポリマー及びモノ スクシニルジメチルβ-シクロデキストリンからなる群から選択される、請求の 範囲第1項記載の組成物。 15.前記シクロデキストリンが、2-ヒドロキシプロピル-β-シクロデキストリン である、請求の範囲第12項記載の組成物。 16.前記リポソーム組成物が、さらに、生体臓器内の所望の位置を標的する手段 を含む、請求の範囲第1項記載の組成物。 17.前記手段が、糖、糖脂質及びタンパク質からなる群から選択された分子の一 部との結合によるものである、請求の範囲第16項記載の組成物。 18.前記タンパク質が、抗体である、請求の範囲第15項記載の組成物。 19.化合物を被包しているリポソームを投与することを含み、このリポソームが さらにシクロデキストリンを被包しているような、動物における生物学的活性化 合物の半減期を延長する方法。 20.前記リポソームが、単層膜、多重層及び多胞体リポソームの群から選択され た、請求の範囲第19項記載の組成物。 21.前記生物学的活性化合物の水への溶解度が、該シクロデキストリン非存在下 で、1μg/ml以上である、請求の範囲第19項記載の組成物。 22.前記シクロデキストリンが、該組成物中に、約10mg/ml〜約400mg/mlの量で 存在する、請求の範囲第19項記載の組成物。 23.前記シクロデキストリンが、α-シクロデキストリン、β-シクロデキストリ ン、γ-シクロデキストリン、メチルシクロデキストリン、エチルシクロデキス トリン、ヒドロキシエチルシクロデキストリン、ヒドロキシプロピルシクロデキ ストリン、分枝したシクロデキストリン、シクロデキストリンポリマー及びモノ スクシニルジメチルβ-シクロデキストリンからなる群から選択される、請求の 範囲第22項記載の組成物。 24.前記シクロデキストリンが、2-ヒドロキシプロピル-β-シクロデキストリン である、請求の範囲第23項記載の組成物。 25.前記化合物が、抗腫瘍薬、抗感染症薬、抗うつ薬、抗ウイルス薬、抗侵害受 容薬、抗不安薬及びホルモンからなる群から選択された、請求の範囲第19項記載 の組成物。 26.前記化合物が、抗腫瘍薬である、請求の範囲第19項記載の組成物。 27.前記化合物が、抗感染症薬である、請求の範囲第19項記載の組成物。 28.前記化合物が、抗ウイルス薬である、請求の範囲第19項記載の組成物。 29.前記化合物が、抗不安薬である、請求の範囲第19項記載の組成物。 30.前記化合物が、抗うつ薬である、請求の範囲第19項記載の組成物。 31.前記化合物が、ホルモンである、請求の範囲第19項記載の組成物。 32.前記化合物が、抗侵害受容薬である、請求の範囲第19項記載の組成物。 33.前記シクロデキストリンが、該リポソーム中に、約10mg/ml〜約400mg/mlの 量で存在する、請求の範囲第19項記載の組成物。 34.前記シクロデキストリンが、α-シクロデキストリン、β-シクロデキストリ ン、γ-シクロデキストリン、メチルシクロデキストリン、エチルシクロデキス トリン、ヒドロキシエチルシクロデキストリン、ヒドロキシプロピルシクロデキ ストリン、分枝したシクロデキストリン、シクロデキストリンポリマー及びモノ スクシニルジメチルβ-シクロデキストリンからなる群から選択される、請求の 範囲第19項記載の組成物。 35.前記シクロデキストリンが、2-ヒドロキシプロピル-β-シクロデキストリン である、請求の範囲第34項記載の組成物。 36.個体の病態生理学的状態を、リポソーム組成物を該個体に投与することで治 療する方法で、該組成物が、該リポソーム内に被包された治療的に有効量の生物 学的活性化合物を含み、該リポソーム組成物がさらにシクロデキストリンを被包 している方法。 37.前記リポソームが、単層膜、多重層及び多胞体リポソームの群から選択され た、請求の範囲第36項記載の組成物。 38.前記生物学的活性化合物の水への溶解度が、シクロデキストリン非存在下で 、1μg/ml以上である、請求の範囲第36項記載の組成物。 39.前記化合物が、抗腫瘍薬、抗感染症薬、抗うつ薬、抗ウイルス薬、抗侵害受 容薬、抗不安薬及びホルモンからなる群から選択された、請求の範囲第36項記載 の組成物。 40.前記化合物が、抗腫瘍薬である、請求の範囲第36項記載の組成物。 41.前記化合物が、抗感染症薬である、請求の範囲第36項記載の組成物。 42.前記化合物が、抗ウイルス薬である、請求の範囲第36項記載の組成物。 43.前記化合物が、抗不安薬である、請求の範囲第36項記載の組成物。 44.前記化合物が、抗うつ薬である、請求の範囲第36項記載の組成物。 45.前記化合物が、ホルモンである、請求の範囲第36項記載の組成物。 46.前記化合物が、抗侵害受容薬である、請求の範囲第36項記載の組成物。 含む、請求の範囲第1項記載の組成物。 47.前記シクロデキストリンが、該組成物中に、約10mg/ml〜約400mg/mlの量で 存在する、請求の範囲第36項記載の組成物。 48.前記シクロデキストリンが、α-シクロデキストリン、β-シクロデキストリ ン、γ-シクロデキストリン、メチルシクロデキストリン、エチルシクロデキス トリン、ヒドロキシエチルシクロデキストリン、ヒドロキシプロピルシクロデキ ストリン、分枝したシクロデキストリン、シクロデキストリンポリマー及びモノ スクシニルジメチルβ-シクロデキストリンからなる群から選択される、請求の 範囲第36項記載の組成物。 49.前記シクロデキストリンが、2-ヒドロキシプロピル-β-シクロデキストリン である、請求の範囲第48項記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5113593A | 1993-04-22 | 1993-04-22 | |
US051,135 | 1993-04-22 | ||
PCT/US1994/004490 WO1994023697A1 (en) | 1993-04-22 | 1994-04-22 | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08509230A true JPH08509230A (ja) | 1996-10-01 |
JP3545403B2 JP3545403B2 (ja) | 2004-07-21 |
Family
ID=21969560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52359394A Expired - Fee Related JP3545403B2 (ja) | 1993-04-22 | 1994-04-22 | 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5759573A (ja) |
EP (1) | EP0695169B1 (ja) |
JP (1) | JP3545403B2 (ja) |
AT (1) | ATE227979T1 (ja) |
AU (1) | AU6818094A (ja) |
CA (1) | CA2161225C (ja) |
DE (1) | DE69431750T2 (ja) |
DK (1) | DK0695169T3 (ja) |
ES (1) | ES2188612T3 (ja) |
HK (1) | HK1013258A1 (ja) |
PT (1) | PT695169E (ja) |
WO (1) | WO1994023697A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009517402A (ja) * | 2005-11-28 | 2009-04-30 | ディー. ロウェ,バーノン | 腎毒性の低減に有用な組成物及びその使用方法 |
JP2010047611A (ja) * | 2001-04-10 | 2010-03-04 | Univ Federal De Minas Gerais - Ufmg | 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製 |
WO2010113983A1 (ja) * | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
JP2013540824A (ja) * | 2010-10-28 | 2013-11-07 | パシラ ファーマシューティカルズ インコーポレーテッド | 非ステロイド性抗炎症薬の徐放性処方物 |
JP2017502985A (ja) * | 2014-01-14 | 2017-01-26 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 修飾シクロデキストリン複合体をカプセル化するリポソーム組成物およびその使用 |
US11071713B2 (en) | 2009-03-30 | 2021-07-27 | Eisai R&D Management Co., Ltd. | Liposome composition |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
JP2021535922A (ja) * | 2018-09-14 | 2021-12-23 | ファルモサ バイオファーマ インコーポレイテッド | 弱酸性薬物の制御放出のための医薬組成物およびその使用 |
US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
Families Citing this family (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
US5931809A (en) * | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
ES2306462T3 (es) | 1996-12-13 | 2008-11-01 | Novartis Vaccines And Diagnostics, Inc. | Analisis y separacion de proteinas del factor de crecimiento derivadas de plaquetas. |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US6443949B2 (en) * | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
AU735588B2 (en) | 1997-09-18 | 2001-07-12 | Pacira Pharmaceuticals, Inc. | Sustained-release liposomal anesthetic compositions |
CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
ES2384094T3 (es) | 1997-11-14 | 2012-06-29 | Pacira Pharmaceuticals, Inc. | Producción de liposomas multivesiculares |
AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
BR9910089A (pt) | 1998-05-01 | 2004-06-08 | Chiron Corp | Composições e antìgenos de neisseria meningitidis |
US6740643B2 (en) * | 1999-01-21 | 2004-05-25 | Mirus Corporation | Compositions and methods for drug delivery using amphiphile binding molecules |
KR20010112301A (ko) * | 1999-03-02 | 2001-12-20 | 질레스피 카롤 | 리포좀내에 생활성 복합체의 포집 |
RU2245366C2 (ru) | 1999-04-30 | 2005-01-27 | Чирон С.Р.Л. | Антиген neisseria, кодирующая его нуклеиновая кислота, их использование |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
AUPQ259399A0 (en) | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
EP2275552B1 (en) | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
US20070219363A1 (en) * | 1999-11-29 | 2007-09-20 | Budker Vladimir G | Chelating Compound for Drug Delivery |
WO2001085093A2 (en) | 1999-12-23 | 2001-11-15 | Neurochem, Inc. | Compounds and methods for modulating cerebral amyloid angiopathy |
PT2289545T (pt) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Vacina de omv suplementada contra meningococos |
US20020082205A1 (en) | 2000-03-08 | 2002-06-27 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
DE60134275D1 (de) | 2000-06-15 | 2008-07-10 | Novartis Vaccines & Diagnostic | Polynukleotide zur bestimmung von kolonkrebs |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
US20020160991A1 (en) * | 2000-12-04 | 2002-10-31 | Liming Shao | Orally-bioavailable formulations of fentanyl and congeners thereof |
CA2430379A1 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
AU2002303261A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
JP3966819B2 (ja) | 2001-05-24 | 2007-08-29 | キム,スーギョン | 毛嚢に存在する新規の第2ケラチノサイト成長因子類似体 |
FR2827516B1 (fr) * | 2001-07-19 | 2003-09-19 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone |
BRPI0105509B8 (pt) * | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
RU2316591C2 (ru) | 2001-11-09 | 2008-02-10 | Джорджтаун Юниверсити | Новые изоформы ингибитора роста васкулярных эндотелиальных клеток |
ES2312649T3 (es) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
DE60326931D1 (de) | 2002-01-08 | 2009-05-14 | Novartis Vaccines & Diagnostic | In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren |
EP2093233A1 (en) | 2002-03-21 | 2009-08-26 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
CN100518831C (zh) * | 2002-08-15 | 2009-07-29 | 刘云清 | 固体纳米药物及其制备方法 |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
EP2279746B1 (en) | 2002-11-15 | 2013-10-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
PT2270048E (pt) | 2002-12-24 | 2016-02-10 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
WO2004074321A2 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
US7655231B2 (en) | 2003-02-19 | 2010-02-02 | Pfizer Inc. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
WO2005023767A2 (en) | 2003-09-10 | 2005-03-17 | Brentwood Equities Ltd. | Diastereomers of 4-aryloxy-3-hydroxypiperidines |
SG166768A1 (en) | 2003-12-23 | 2010-12-29 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
PT1736541E (pt) | 2004-03-29 | 2013-01-31 | Galpharma Co Ltd | Nova proteína galectina 9 modificada e sua utilização |
HUE037549T2 (hu) | 2004-04-07 | 2018-09-28 | Rinat Neuroscience Corp | Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával |
KR100896697B1 (ko) | 2004-04-09 | 2009-05-14 | (주)아모레퍼시픽 | 고압유화기술에 의한 대황추출물의 경피흡수 촉진방법 및이를 응용한 미백용 피부 외용제 조성물 |
PT1789593T (pt) | 2004-07-09 | 2017-04-24 | Henry M Jackson Found Advancement Military Medicine Inc | Formas solúveis de glicoproteína g de vírus hendra |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
EP2298807A3 (en) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
US7666442B2 (en) * | 2004-08-31 | 2010-02-23 | Tracie Martyn International, Llc | Topical compositions comprising benfotiamine and pyridoxamine |
US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
CN101203529A (zh) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
WO2006110581A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
EP1865981A2 (en) | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e in cancer diagnosis, detection and treatment |
WO2007005754A2 (en) * | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
RU2486204C2 (ru) | 2005-07-22 | 2013-06-27 | Уай'З Терапьютикс Ко., Лтд. | Антитела против сd26 и способы их применения |
US8998881B2 (en) | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
RS57194B1 (sr) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
KR100793824B1 (ko) | 2006-03-06 | 2008-01-11 | (주)아모레퍼시픽 | 하이드록시프로필-베타사이클로 덱스트린을 이용하여가용화된 유용성 생리활성성분을 담지하는 고분자-리포좀나노복합체 |
EP1988920A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
AU2007210862A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist |
EP2044120B1 (en) | 2006-06-07 | 2019-01-30 | BioAlliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
WO2008124176A2 (en) | 2007-04-10 | 2008-10-16 | The Administrators Of The Tulane Educational Fund | Soluble and membrane-anchored forms of lassa virus subunit proteins |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
JP5737944B2 (ja) | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | 間質性膀胱炎の治療 |
RU2528738C2 (ru) | 2007-12-18 | 2014-09-20 | Биоэллаенс К.В. | Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения |
US20090196918A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions |
AU2009234389B2 (en) | 2008-04-10 | 2014-08-21 | Cell Signaling Technology, Inc. | Compositions and methods for detecting EGFR mutations in cancer |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
US9492417B2 (en) | 2008-08-21 | 2016-11-15 | The Johns Hopkins University | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
CN102281903B (zh) * | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 降低大分子在生理条件下聚集的方法和配方 |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
PL2510947T3 (pl) | 2009-04-14 | 2016-09-30 | Kompozycje do immunizacji przeciwko Staphylococcus aureus | |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
CA2763365C (en) | 2009-05-29 | 2016-09-13 | Cydex Pharmaceuticals, Inc. | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
CN102770443A (zh) | 2009-07-16 | 2012-11-07 | 诺华有限公司 | 脱毒大肠杆菌免疫原 |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
TWI552760B (zh) | 2010-02-24 | 2016-10-11 | 雷那特神經科學股份有限公司 | 拮抗劑抗-il-7受體抗體及方法 |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
SA111320266B1 (ar) | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
US10842849B2 (en) | 2011-02-28 | 2020-11-24 | The Schepens Eye Research Institute, Inc. | Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy |
MX2013010980A (es) | 2011-04-07 | 2013-10-30 | Procter & Gamble | Composiciones de limpieza personal con deposito mejorado de microcapsulas de poliacrilato. |
JP5869663B2 (ja) | 2011-04-07 | 2016-02-24 | ザ プロクター アンド ギャンブルカンパニー | ポリアクリレートマイクロカプセルの付着が増大したシャンプー組成物 |
EP2694031B1 (en) | 2011-04-07 | 2015-07-08 | The Procter and Gamble Company | Conditioner compositions with increased deposition of polyacrylate microcapsules |
US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
WO2013028527A1 (en) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions and methods for treating cancer |
SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
BR112014014824A2 (pt) | 2011-12-22 | 2019-09-24 | Rinat Neuroscience Corp | anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
CA2871820C (en) | 2012-05-10 | 2020-11-03 | Painreform Ltd. | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
HUE035607T2 (en) | 2012-06-25 | 2018-05-28 | Brigham & Womens Hospital Inc | Targeted therapeutic agents |
EP2866829B1 (en) | 2012-07-02 | 2017-12-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Paramyxovirus and methods of use |
US10022326B2 (en) * | 2012-07-18 | 2018-07-17 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
JP2015536339A (ja) | 2012-11-09 | 2015-12-21 | ファイザー・インク | 血小板由来増殖因子b特異的抗体ならびにこれらの組成物および使用 |
CN105473154A (zh) | 2013-03-12 | 2016-04-06 | 通用医疗公司 | 修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途 |
EP3594244A1 (en) | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
SG11201508264UA (en) | 2013-05-07 | 2015-11-27 | Rinat Neuroscience Corp | Anti-glucagon receptor antibodies and methods of use thereof |
US20170172922A1 (en) * | 2013-05-15 | 2017-06-22 | Hsu-Shen WU | Micron taiwanofungus camphoratus liposome structure |
TWM473835U (zh) * | 2013-05-15 | 2014-03-11 | Wu xu sheng | 微米牛樟芝微脂載體結構 |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
SG11201600171SA (en) | 2013-08-02 | 2016-02-26 | Pfizer | Anti-cxcr4 antibodies and antibody-drug conjugates |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
AU2014362307A1 (en) | 2013-12-11 | 2016-06-30 | The General Hospital Corporation | Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
IL290488B1 (en) | 2015-04-13 | 2024-03-01 | Pfizer | Therapeutic antibodies and their uses |
TWM513697U (zh) * | 2015-06-26 | 2015-12-11 | Ma Shen Kai Ruei Co Ltd | 仿生物間質系統的載體結構 |
US10877045B2 (en) | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
JP7068160B2 (ja) | 2015-07-21 | 2022-05-16 | 武田薬品工業株式会社 | 第XIIa因子のモノクローナル抗体阻害剤 |
US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
NZ739871A (en) | 2015-08-19 | 2022-05-27 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
EP3922645A1 (en) | 2015-09-15 | 2021-12-15 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3365369A1 (en) | 2015-10-23 | 2018-08-29 | Pfizer Inc | Anti-il-2 antibodies and compositions and uses thereof |
WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
WO2017079563A1 (en) | 2015-11-06 | 2017-05-11 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | 抗pd-1抗体及其治疗用途 |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
KR20180098625A (ko) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
EP3405490B1 (en) | 2016-01-21 | 2021-10-20 | Pfizer Inc. | Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses |
WO2018094253A1 (en) | 2016-11-18 | 2018-05-24 | Pacira Pharmaceuticals, Inc. | Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same |
AU2018226646A1 (en) | 2017-03-03 | 2019-09-19 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
US20200056190A1 (en) | 2017-03-16 | 2020-02-20 | Pfizer Inc. | Tyrosine prototrophy |
WO2018191548A2 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
WO2018231772A1 (en) | 2017-06-13 | 2018-12-20 | Bostongene Corporation | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | ANTI-NUCLEOLIN ANTIBODIES |
CA3078460A1 (en) | 2017-10-04 | 2019-04-11 | Opko Pharmaceuticals, Llc | Articles and methods directed to personalized therapy of cancer |
WO2019094648A1 (en) * | 2017-11-08 | 2019-05-16 | L.E.A.F. Holdings Group Llc | Platinum complexes and uses thereof |
MX2020008184A (es) | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
WO2019152705A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Antibodies specific for cd70 and their uses |
WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
KR20230146098A (ko) | 2018-05-23 | 2023-10-18 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
AU2019274654B2 (en) | 2018-05-23 | 2023-07-20 | Pfizer Inc. | Antibodies specific for CD3 and uses thereof |
JP2022518147A (ja) | 2019-01-03 | 2022-03-14 | アンダードッグ・ファーマシューティカルズ・インコーポレイテッド | シクロデキストリン二量体、それらの組成物、及びそれらの使用 |
JP2022538499A (ja) | 2019-07-03 | 2022-09-02 | ボストンジーン コーポレイション | サンプル調製、サンプルシークエンシング、およびシークエンシングデータのバイアス補正と品質管理のためのシステムならびに方法 |
EP4041308A1 (en) | 2019-10-07 | 2022-08-17 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CA3152623A1 (en) | 2019-10-11 | 2021-04-15 | Richard D. Cummings | Anti-tn antibodies and uses thereof |
EP4093426A1 (en) | 2020-01-24 | 2022-11-30 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
WO2021224850A1 (en) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Mask peptides and masked anti-ptk7 antibodies comprising such |
CN116323668A (zh) | 2020-07-17 | 2023-06-23 | 辉瑞公司 | 治疗性抗体及其用途 |
US20230287455A1 (en) | 2020-07-30 | 2023-09-14 | Pfizer Inc. | Cells Having Gene Duplications and Uses Thereof |
EP4203989A2 (en) | 2020-09-03 | 2023-07-05 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
CN112190498B (zh) * | 2020-10-31 | 2022-03-25 | 华南理工大学 | 一种具有水溶性的茶碱和环糊精包合物及其制备方法 |
WO2022120256A2 (en) | 2020-12-04 | 2022-06-09 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US20220372580A1 (en) | 2021-04-29 | 2022-11-24 | Bostongene Corporation | Machine learning techniques for estimating tumor cell expression in complex tumor tissue |
WO2023012627A1 (en) | 2021-08-02 | 2023-02-09 | Pfizer Inc. | Improved expression vectors and uses thereof |
US20230245479A1 (en) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Machine learning techniques for cytometry |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
WO2024015561A1 (en) | 2022-07-15 | 2024-01-18 | Bostongene Corporation | Techniques for detecting homologous recombination deficiency (hrd) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0261719A3 (en) * | 1986-09-23 | 1990-10-10 | Akzo N.V. | Thermochemiluminescent cyclodextrin complexes |
GB8704171D0 (en) * | 1987-02-23 | 1987-04-01 | Clayton Found Res | Multivesicular liposomes |
US5236907A (en) * | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
US5180716A (en) * | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
GB9126209D0 (en) * | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
-
1994
- 1994-04-22 JP JP52359394A patent/JP3545403B2/ja not_active Expired - Fee Related
- 1994-04-22 WO PCT/US1994/004490 patent/WO1994023697A1/en active IP Right Grant
- 1994-04-22 DE DE69431750T patent/DE69431750T2/de not_active Expired - Lifetime
- 1994-04-22 PT PT94916558T patent/PT695169E/pt unknown
- 1994-04-22 ES ES94916558T patent/ES2188612T3/es not_active Expired - Lifetime
- 1994-04-22 DK DK94916558T patent/DK0695169T3/da active
- 1994-04-22 AT AT94916558T patent/ATE227979T1/de not_active IP Right Cessation
- 1994-04-22 EP EP94916558A patent/EP0695169B1/en not_active Expired - Lifetime
- 1994-04-22 AU AU68180/94A patent/AU6818094A/en not_active Abandoned
- 1994-04-22 CA CA002161225A patent/CA2161225C/en not_active Expired - Lifetime
- 1994-04-22 US US08/535,256 patent/US5759573A/en not_active Expired - Lifetime
-
1998
- 1998-12-22 HK HK98114611A patent/HK1013258A1/xx not_active IP Right Cessation
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010047611A (ja) * | 2001-04-10 | 2010-03-04 | Univ Federal De Minas Gerais - Ufmg | 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製 |
JP2013231079A (ja) * | 2005-11-28 | 2013-11-14 | Verrow Pharmaceuticals Inc | 腎毒性の低減に有用な組成物及びその使用方法 |
JP2009517402A (ja) * | 2005-11-28 | 2009-04-30 | ディー. ロウェ,バーノン | 腎毒性の低減に有用な組成物及びその使用方法 |
US9968583B2 (en) | 2009-03-30 | 2018-05-15 | Eisai R & D Management Co., Ltd. | Method of manufacture of liposome composition |
WO2010113983A1 (ja) * | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
JP2014167012A (ja) * | 2009-03-30 | 2014-09-11 | Eisai R & D Management Co Ltd | リポソーム組成物の製造方法 |
JP5622719B2 (ja) * | 2009-03-30 | 2014-11-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
US11071713B2 (en) | 2009-03-30 | 2021-07-27 | Eisai R&D Management Co., Ltd. | Liposome composition |
US10729651B2 (en) | 2010-10-28 | 2020-08-04 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
JP2018065877A (ja) * | 2010-10-28 | 2018-04-26 | パシラ ファーマシューティカルズ インコーポレーテッド | 非ステロイド性抗炎症薬の徐放性処方物 |
US9974744B2 (en) | 2010-10-28 | 2018-05-22 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
US10123974B2 (en) | 2010-10-28 | 2018-11-13 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
US10610486B2 (en) | 2010-10-28 | 2020-04-07 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
US10617642B2 (en) | 2010-10-28 | 2020-04-14 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
US10675245B2 (en) | 2010-10-28 | 2020-06-09 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
JP2013540824A (ja) * | 2010-10-28 | 2013-11-07 | パシラ ファーマシューティカルズ インコーポレーテッド | 非ステロイド性抗炎症薬の徐放性処方物 |
JP2016040332A (ja) * | 2010-10-28 | 2016-03-24 | パシラ ファーマシューティカルズ インコーポレーテッド | 非ステロイド性抗炎症薬の徐放性処方物 |
JP2017502985A (ja) * | 2014-01-14 | 2017-01-26 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 修飾シクロデキストリン複合体をカプセル化するリポソーム組成物およびその使用 |
US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
JP2021535922A (ja) * | 2018-09-14 | 2021-12-23 | ファルモサ バイオファーマ インコーポレイテッド | 弱酸性薬物の制御放出のための医薬組成物およびその使用 |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Also Published As
Publication number | Publication date |
---|---|
PT695169E (pt) | 2003-04-30 |
WO1994023697A1 (en) | 1994-10-27 |
CA2161225A1 (en) | 1994-10-27 |
CA2161225C (en) | 2003-07-01 |
EP0695169A4 (en) | 1998-02-04 |
HK1013258A1 (en) | 1999-08-20 |
DE69431750T2 (de) | 2003-04-03 |
EP0695169A1 (en) | 1996-02-07 |
ATE227979T1 (de) | 2002-12-15 |
DK0695169T3 (da) | 2003-03-17 |
DE69431750D1 (de) | 2003-01-02 |
AU6818094A (en) | 1994-11-08 |
JP3545403B2 (ja) | 2004-07-21 |
EP0695169B1 (en) | 2002-11-20 |
ES2188612T3 (es) | 2003-07-01 |
US5759573A (en) | 1998-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3545403B2 (ja) | 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法 | |
Filipović-Grčić et al. | Mucoadhesive chitosan-coated liposomes: characteristics and stability | |
CA2303432C (en) | Modulation of drug loading in multivesicular liposomes | |
US20050208122A1 (en) | Biodegradable biocompatible implant and method of manufacturing same | |
EP2645991B1 (en) | Aptamer bioconjugate drug delivery device | |
Guo et al. | Direct site-specific treatment of skin cancer using doxorubicin-loaded nanofibrous membranes | |
Green-Sadan et al. | Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats | |
JP5429642B2 (ja) | 薬剤の局所導出を対象とした注射可能なポリマー/脂質ブレンド | |
JP2005532355A (ja) | ステルス脂質ナノカプセル、その製造方法、およびその、活性要素用キャリヤーとしての使用 | |
JP2009507049A (ja) | リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤 | |
CN106474064B (zh) | 一种蒿甲醚纳米脂质体及其制备方法与应用 | |
Zhang et al. | PEGylated nanostructured lipid carriers loaded with 10‐hydroxycamptothecin: an efficient carrier with enhanced anti‐tumour effects against lung cancer | |
EP3138557B1 (en) | Liposome composition and method for producing same | |
Oommen et al. | Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system | |
WO2008130137A1 (en) | Anionic lipid nanosphere and preparation method of the same | |
Singh et al. | Novel drug delivery system & it’s future: an overview | |
CN108309940B (zh) | β-榄香烯与铂类药物共载脂质体及其制备方法 | |
US20210322326A1 (en) | Hydrogel particle carriers for delivery of therapeutic/diagnostic agents | |
Binaymotlagh et al. | Liposome–Hydrogel Composites for Controlled Drug Delivery Applications | |
KR101686341B1 (ko) | 약물 표적화를 위한 초상자성 산화철 나노입자의 제조방법 | |
CN110302159B (zh) | 一种还原敏感脂质药物组合物及其制备方法和应用 | |
CN116196279B (zh) | 一种蟾酥提取物无胆固醇脂质体及其制备方法和应用 | |
Kannadasan et al. | A review: nano particle drug delivery system | |
Prajapati et al. | An Approach in Novel Drug Delivery Systems Future Prospects and Opportunities | |
Talevi et al. | An Introduction to Pharmacokinetics: From Conventional to Advanced Systemic Drug Delivery Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040309 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040408 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090416 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090416 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100416 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100416 Year of fee payment: 6 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100416 Year of fee payment: 6 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110416 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120416 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120416 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130416 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130416 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140416 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |